OGT 2115|cas:853929-59-6|西域试剂

OGT 2115,98.09%

产品编号：Bellancom-100898| CAS NO：853929-59-6| 分子式：C₂₄H₁₆BrFN₂O₄| 分子量：495.30

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-100898	￥800.00	杭州北京（现货）
Bellancom-100898	￥1400.00	杭州北京（现货）
Bellancom-100898	￥3000.00	杭州北京（现货）
Bellancom-100898	￥5000.00	杭州北京（现货）
Bellancom-100898	￥8000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

OGT 2115

产品介绍

OGT 2115 是一种有效的，细胞可渗透且口服活性的乙酰肝素酶 (heparanase) 抑制剂，IC₅₀ 为 0.4 μM。OGT 2115 具有抗血管生成特性 (IC₅₀ 为 1 μM)。OGT 2115 还抑制硫酸乙酰肝素的降解活性。

生物活性

OGT 2115 is a potent, cell-permeable and orally active heparanase inhibitor with an IC₅₀ of 0.4 μM. OGT 2115 has anti-angiogenic properties (IC₅₀ of 1 μM). OGT 2115 also inhibits heparan sulfate degradation activity.

体外研究

Heparanase InhibitorOGT 2115 can suppress metastasis induced by endoplasmic reticulum (ER) stress in breast cancer cells, although not significantly. However, compared with the control group, the number and rate of migrated cells are significantly reduced following the exposure of the cells to Tunicamycin + OGT 2115. OGT 2115 significantly inhibits the invasion and migration induced by Adriamycin. Furthermore, the MTT assay results show that OGT 2115 does not decrease the anti-proliferative effect of Adriamycin.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

When administered to mice, OGT 2115 (Compound 12d) shows a plasma concentration of ~10x the heparanase IC₅₀ following oral dosing at 20 mg/kg.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

When administered to mice, OGT 2115 (Compound 12d) shows a plasma concentration of ~10x the heparanase IC₅₀ following oral dosing at 20 mg/kg.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 11.36 mg/mL (22.94 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.0190 mL	10.0949 mL	20.1898 mL
5 mM	0.4038 mL	2.0190 mL	4.0380 mL
10 mM	0.2019 mL	1.0095 mL	2.0190 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 0.5% CMC-Na/saline water
Solubility: 10 mg/mL (20.19 mM); Suspended solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 1.14 mg/mL (2.30 mM); Clear solution

此方案可获得 ≥ 1.14 mg/mL (2.30 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 11.4 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。